TABLE 4.

Drug specific model parameters for panitumumab, emibetuzumab, amivantamab.

Parameter	Value	Unit	Reference
Panitumumab Valency	2	-	Yang et al., 2001; Ma et al., 2009
Panitumumab Dosing Interval	2	weeks	Ma et al., 2009
Panitumumab Half-Life	16	days	Yang et al., 2001; Ma et al., 2009
Panitumumab KD for EGFR	0.05	nM	Yang et al., 2001; Ma et al., 2009
Emibetuzumab Valency	-	2	Liu et al., 2014; Rosen et al., 2017
Emibetuzumab Dosing Interval	2	weeks	Rosen et al. (2017)
Emibetuzumab Half-Life	16	days	Liu et al., 2014; Rosen et al., 2017
Emibetuzumab KD for c-Met	0.1	nM	Liu et al., 2014; Rosen et al., 2017
Amivantamab Valency	-	1	Jarantow et al., 2015
Amivantamab Dosing Interval	2	weeks	Rybrevant, 2021
Amivantamab Half-Life	11	days	Rybrevant, 2021
Amivantamab KD for EGFR	1.4	nM	Jarantow et al. (2015)
Amivantamab KD for c-Met	0.04	nM	Jarantow et al. (2015)
Drug Molecular Weight	150,000	Daltons	Assumed typical mAb MW for all drugs
Pdist12	0.19	-	Partition coefficient between central and peripheral compartments assumed typical (Betts et al., 2018)
Tdist12	35	hours	Half-life of intercompartmental clearance between central and peripheral compartments assumed typical (Betts et al., 2018)